These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 2473187

  • 1. Drug discrimination in human postaddicts: agonist-antagonist opioids.
    Preston KL, Bigelow GE, Bickel WK, Liebson IA.
    J Pharmacol Exp Ther; 1989 Jul; 250(1):184-96. PubMed ID: 2473187
    [Abstract] [Full Text] [Related]

  • 2. Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure.
    Preston KL, Bigelow GE.
    J Pharmacol Exp Ther; 1994 Oct; 271(1):48-60. PubMed ID: 7525929
    [Abstract] [Full Text] [Related]

  • 3. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure.
    Jones HE, Bigelow GE, Preston KL.
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1350-61. PubMed ID: 10336526
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Assessment of buprenorphine in a drug discrimination procedure in humans.
    Bigelow GE, Preston KL.
    NIDA Res Monogr; 1992 Jun; 121():28-37. PubMed ID: 1406908
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers.
    Preston KL, Bigelow GE.
    J Pharmacol Exp Ther; 1993 Feb; 264(2):813-23. PubMed ID: 7679737
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists.
    Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA.
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1130-41. PubMed ID: 8968334
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.
    Strain EC, Preston KL, Liebson IA, Bigelow GE.
    J Pharmacol Exp Ther; 1992 Jun; 261(3):985-93. PubMed ID: 1376362
    [Abstract] [Full Text] [Related]

  • 15. Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts.
    Preston KL, Bigelow GE, Liebson IA.
    J Pharmacol Exp Ther; 1987 Mar; 240(3):900-10. PubMed ID: 3559982
    [Abstract] [Full Text] [Related]

  • 16. Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers.
    Lamas X, Farre M, Cami J.
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1485-92. PubMed ID: 8138958
    [Abstract] [Full Text] [Related]

  • 17. Drug discrimination in human post-addicts: agonist/antagonist opioids.
    Preston K, Bigelow G, Bickel W, Liebson I.
    NIDA Res Monogr; 1988 Mar; 81():209-15. PubMed ID: 2457160
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Discriminative stimulus effects of buprenorphine in the rat.
    Holtzman SG.
    Psychopharmacology (Berl); 1997 Apr; 130(3):292-9. PubMed ID: 9151365
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.